LOXL2 and neoplasm: To further confirm that CD8+ T cells infiltrate into tumor tissues after combination therapy with anti-PD-L1 and LOXL2 inhibition or knockdown, we performed immunohistochemistry (IHC) stains for CD8 in primary and lung metastatic tumor tissues from the combinatorial treatment studies (Fig. 3a and Supplementary Fig. 5a).